1. Sugarman EA, Nagan N, Zhu H, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens. Eur J Hum Genet. 2012; 20(1): 27–32, doi: [10.1038/ejhg.2011.134](http://dx.doi.org/10.1038/ejhg.2011.134), indexed in Pubmed: [21811307](https://www.ncbi.nlm.nih.gov/pubmed/21811307).
2. Verhaart IEC, Robertson A, Leary R, et al. A multi-source approach to determine SMA incidence and research ready population. J Neurol. 2017; 264(7): 1465–1473, doi: [10.1007/s00415-017-8549-1](http://dx.doi.org/10.1007/s00415-017-8549-1), indexed in Pubmed: [28634652](https://www.ncbi.nlm.nih.gov/pubmed/28634652).
3. Mercuri E, Finkel RS, Muntoni F, et al. SMA Care Group. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018; 28(2): 103–115, doi: [10.1016/j.nmd.2017.11.005](http://dx.doi.org/10.1016/j.nmd.2017.11.005), indexed in Pubmed: [29290580](https://www.ncbi.nlm.nih.gov/pubmed/29290580).
4. Ruano L, Melo C, Silva MC, et al. The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies. Neuroepidemiology. 2014; 42(3): 174–183, doi: [10.1159/000358801](http://dx.doi.org/10.1159/000358801), indexed in Pubmed: [24603320](https://www.ncbi.nlm.nih.gov/pubmed/24603320).
5. Shoukier M, Neesen J, Sauter SM, et al. Expansion of mutation spectrum, determination of mutation cluster regions and predictive structural classification of SPAST mutations in hereditary spastic paraplegia. Eur J Hum Genet. 2009; 17(2): 187–194, doi: [10.1038/ejhg.2008.147](http://dx.doi.org/10.1038/ejhg.2008.147), indexed in Pubmed: [18701882](https://www.ncbi.nlm.nih.gov/pubmed/18701882).
6. Scarlato M, Nuara A, Gerevini S, et al. A new double-trouble phenotype: fascioscapulohumeral muscular dystrophy ameliorates hereditary spastic paraparesis due to spastin mutation. J Neurol. 2015; 262(2): 476–478, doi: [10.1007/s00415-014-7606-2](http://dx.doi.org/10.1007/s00415-014-7606-2), indexed in Pubmed: [25511172](https://www.ncbi.nlm.nih.gov/pubmed/25511172).
7. Mendez HM, Opitz JM. Noonan syndrome: a review. Am J Med Genet. 1985; 21(3): 493–506, doi: [10.1002/ajmg.1320210312](http://dx.doi.org/10.1002/ajmg.1320210312), indexed in Pubmed: [3895929](https://www.ncbi.nlm.nih.gov/pubmed/3895929).
8. van der Burgt I. Noonan syndrome. Orphanet J Rare Dis. 2007; 2: 4, doi: [10.1186/1750-1172-2-4](http://dx.doi.org/10.1186/1750-1172-2-4), indexed in Pubmed: [17222357](https://www.ncbi.nlm.nih.gov/pubmed/17222357).
9. Tartaglia M, Mehler EL, Goldberg R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001; 29(4): 465–468, doi: [10.1038/ng772](http://dx.doi.org/10.1038/ng772), indexed in Pubmed: [11704759](https://www.ncbi.nlm.nih.gov/pubmed/11704759).
10. Dinopoulos A, Papadopoulou A, Manta P, et al. Coinheritance of Noonan syndrome and Becker muscular dystrophy. Neuromuscul Disord. 2010; 20(1): 61–63, doi: [10.1016/j.nmd.2009.08.008](http://dx.doi.org/10.1016/j.nmd.2009.08.008), indexed in Pubmed: [19875288](https://www.ncbi.nlm.nih.gov/pubmed/19875288).
11. Sharland M, Burch M, McKenna WM, et al. A clinical study of Noonan syndrome. Arch Dis Child. 1992; 67(2): 178–183, doi: [10.1136/adc.67.2.178](http://dx.doi.org/10.1136/adc.67.2.178), indexed in Pubmed: [1543375](https://www.ncbi.nlm.nih.gov/pubmed/1543375).
12. Croonen EA, Essink M, van der Burgt I, et al. Motor performance in children with Noonan syndrome. Am J Med Genet A. 2017; 173(9): 2335–2345, doi: [10.1002/ajmg.a.38322](http://dx.doi.org/10.1002/ajmg.a.38322), indexed in Pubmed: [28627718](https://www.ncbi.nlm.nih.gov/pubmed/28627718).
13. Fernández RM, Peciña A, Muñoz-Cabello B, et al. Co-segregation of a homozygous SMN1 deletion and a heterozygous PMP22 duplication in a patient. Clin Case Rep. 2016; 4(9): 879–884, doi: [10.1002/ccr3.645](http://dx.doi.org/10.1002/ccr3.645), indexed in Pubmed: [27648268](https://www.ncbi.nlm.nih.gov/pubmed/27648268).
14. Aartsma-Rus A. FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides. Nucleic Acid Ther. 2017; 27(2): 67–69, doi: [10.1089/nat.2017.0665](http://dx.doi.org/10.1089/nat.2017.0665), indexed in Pubmed: [28346110](https://www.ncbi.nlm.nih.gov/pubmed/28346110).
15. Chiriboga CA. Nusinersen for the treatment of spinal muscular atrophy. Expert Rev Neurother. 2017; 17(10): 955–962, doi: [10.1080/14737175.2017.1364159](http://dx.doi.org/10.1080/14737175.2017.1364159), indexed in Pubmed: [28884620](https://www.ncbi.nlm.nih.gov/pubmed/28884620).
16. Wadman RI, van der Pol WL, Bosboom WMj, et al. Drug treatment for spinal muscular atrophy type I. Cochrane Database Syst Rev. 2011; 1(12): CD006281, doi: [10.1002/14651858.CD006281.pub3](http://dx.doi.org/10.1002/14651858.CD006281.pub3), indexed in Pubmed: [22161399](https://www.ncbi.nlm.nih.gov/pubmed/22161399).
17. Kariyawasam D, Carey KA, Jones KJ, et al. New and developing therapies in spinal muscular atrophy. Paediatr Respir Rev. 2018; 28: 3–10, doi: [10.1016/j.prrv.2018.03.003](http://dx.doi.org/10.1016/j.prrv.2018.03.003), indexed in Pubmed: [29703692](https://www.ncbi.nlm.nih.gov/pubmed/29703692).